Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Cerenis Therapeutics announces formation of Scientific Advisory Board
and expansion of Board of Directors


Toulouse, France & Ann Arbor, Michigan, March 21, 2007 – Cerenis Therapeutics SA (Cerenis), a privately-held pharmaceutical company developing novel HDL therapies to treat cardiovascular and other metabolic diseases, today announced the appointments of H. Bryan Brewer, Jr., M.D., John J.P. Kastelein, M.D., Ph.D., and Jean-Claude Tardif, M.D., to its new Scientific Advisory Board. Cerenis also announced the appointment of Mark Skaletsky as independent director of the Cerenis Board of Directors.

Dr. H. Bryan Brewer, Jr., is director of Lipoprotein and Atherosclerosis Research at the Cardiovascular Research Institute, MedStar Research Institute, in Washington, DC. As chief of the molecular disease branch of the National Heart, Lung, and Blood Institute (NHLBI) from 1976 to 2005, Dr. Brewer's research led to the first published sequences for human plasma apolipoproteins and the initial determination of plasma apolipoproteins metabolism in normal and hyperlipidemic individuals. He also pioneered the use of transgenic vectors to identify genes that modulate lipoprotein metabolism.

Dr. John J.P. Kastelein, a world-renowned lipidologist, is professor of medicine and chairman of the department of vascular medicine at the University of Amsterdam. Dr. Kastelein's research focuses on the molecular bases of hypertriglyceridemia, hypercholesterolemia and low-HDL cholesterol. He has published more than 400 articles about lipids and lipoproteins in leading medical publications. He is also a founder of the Lipid Research Clinic at the Academic Medical Centre of the University of Amsterdam as well as the Dutch National Foundation for the Identification of Familial Hypercholesterolemia.

Dr. Jean-Claude Tardif is associate professor at the faculty of medicine of the Université de Montréal and director of the Research Centre of the Montreal Heart Institute. In 2004 Dr. Tardif was named the first Pfizer Chair in Atherosclerosis at the Université. Leading a team of more than 40 clinicians, Dr. Tardif has conducted extensive research related to different therapeutic strategies to stabilize or reverse atherosclerosis. His research efforts have led to the introduction of new pharmacological approaches and to the development of new technologies targeting cardiovascular disease.

'We welcome the unparalleled clinical and research experience that Doctors Brewer, Kastelein and Tardif bring to the new Cerenis Scientific Advisory Board. Together they represent a major new information resource for Cerenis that will play an important role in both our development program and our plans related to product commercialization as well as licensing and partnership opportunities,' said Jean-Louis Dasseux, Ph.D., M.B.A., CEO and president of Cerenis.

In addition to the formation of the new Cerenis Scientific Advisory Board, the company also announced that Mark Skaletsky, chairman, CEO and president of Trine Pharmaceuticals, Inc., a leading developer of therapies for renal, gastrointestinal and metabolic diseases, has joined the Cerenis Board of Directors. Previously, Mr. Skaletsky served as President and CEO of GelTex Pharmaceuticals, Inc. (acquired by Genzyme in December 2000), Chairman and CEO of Enzytech, Inc., and President and Chief Operating Officer of Biogen, Inc.

'Mark Skaletsky is an industry veteran with more than 25 years of biotechnology experience. He makes an excellent addition to our Board of Directors, and we welcome his broad industry expertise and guidance as we continue to position Cerenis as the leader in HDL product development and commercialization,' said Andre Mueller, chairman of the Cerenis Board of Directors.
-ENDS-


About Cerenis Therapeutics
Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases. Based on pioneering research conducted by the Cerenis


Publisher Contact Information:

Cerenis Therapeutics SA
-
brinkerhoff@cerenis.com

Company profile of Cerenis Therapeutics SA
Past press releases of Cerenis Therapeutics SA.

Data


27,746
Tech investments
From our Online Data Service
17,891
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.